(Q39953290)

English

Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

phase II clinical trial

0 references

adaptive radiation therapy

0 references

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

object named as

Adrian Lee

2

0 references

Mustafa Khasraw

object named as

Mustafa Khasraw

1

0 references

Ganessan Kichenadasse

object named as

Ganessan Kichenadasse

7

0 references

author name string

Sally McCowatt

3

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Zoltan Kerestes

4

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Marc E Buyse

5

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Michael Back

6

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Stephen Ackland

8

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Helen Wheeler

9

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

publication date

2 March 2016

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Journal of Neuro-Oncology

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

128

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

163-171

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009.

1 reference

https://api.crossref.org/works/10.1007%2FS11060-016-2094-0

21 January 2018

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

1 reference

https://api.crossref.org/works/10.1007%2FS11060-016-2094-0

21 January 2018

Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma

1 reference

https://api.crossref.org/works/10.1007%2FS11060-016-2094-0

21 January 2018

Autocrine factors that sustain glioma invasion and paracrine biology in the brain microenvironment.

1 reference

https://api.crossref.org/works/10.1007%2FS11060-016-2094-0

21 January 2018

Expression of integrin alphavbeta3 in gliomas correlates with tumor grade and is not restricted to tumor vasculature

1 reference

https://api.crossref.org/works/10.1007%2FS11060-016-2094-0

21 January 2018

Integrin control of the transforming growth factor-β pathway in glioblastoma.

1 reference

https://api.crossref.org/works/10.1007%2FS11060-016-2094-0

21 January 2018

Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma.

1 reference

https://api.crossref.org/works/10.1007%2FS11060-016-2094-0

21 January 2018

Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme

1 reference

https://api.crossref.org/works/10.1007%2FS11060-016-2094-0

21 January 2018

A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306)

1 reference

https://api.crossref.org/works/10.1007%2FS11060-016-2094-0

21 January 2018

Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency

1 reference

https://api.crossref.org/works/10.1007%2FS11060-016-2094-0

21 January 2018

Validation of real-time methylation-specific PCR to determine O6-methylguanine-DNA methyltransferase gene promoter methylation in glioma.

1 reference

https://api.crossref.org/works/10.1007%2FS11060-016-2094-0

21 January 2018

Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules

1 reference

https://api.crossref.org/works/10.1007%2FS11060-016-2094-0

21 January 2018

Inhibition of angiogenesis by non-toxic doses of temozolomide

1 reference

https://api.crossref.org/works/10.1007%2FS11060-016-2094-0

21 January 2018

New (alternative) temozolomide regimens for the treatment of glioma

1 reference

https://api.crossref.org/works/10.1007%2FS11060-016-2094-0

21 January 2018

Salvage chemotherapy with procarbazine and fotemustine combination in the treatment of temozolomide treated recurrent glioblastoma patients.

1 reference

https://api.crossref.org/works/10.1007%2FS11060-016-2094-0

21 January 2018

A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

1 reference

https://api.crossref.org/works/10.1007%2FS11060-016-2094-0

21 January 2018

Phase I study of temozolamide (TMZ) combined with procarbazine (PCB) in patients with gliomas

1 reference

https://api.crossref.org/works/10.1007%2FS11060-016-2094-0

21 January 2018

Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma

1 reference

https://api.crossref.org/works/10.1007%2FS11060-016-2094-0

21 January 2018

Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial

1 reference

https://api.crossref.org/works/10.1007%2FS11060-016-2094-0

21 January 2018

Randomized trial of chemoradiotherapy and adjuvant chemotherapy with nimustine (ACNU) versus nimustine plus procarbazine for newly diagnosed anaplastic astrocytoma and glioblastoma (JCOG0305).

1 reference

https://api.crossref.org/works/10.1007%2FS11060-016-2094-0

21 January 2018

Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03.

1 reference

https://api.crossref.org/works/10.1007%2FS11060-016-2094-0

21 January 2018

Long-term survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomide

1 reference

https://api.crossref.org/works/10.1007%2FS11060-016-2094-0

21 January 2018

Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States.

1 reference

https://api.crossref.org/works/10.1007%2FS11060-016-2094-0

21 January 2018

One-sample multiple testing procedure for phase II clinical trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/26935578

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Differential effects of procarbazine and methylnitrosourea on the accumulation of O6-methylguanine and the depletion and recovery of O6-alkylguanine-DNA alkyltransferase in rat tissues

1 reference

https://pubmed.ncbi.nlm.nih.gov/26935578

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cilengitide Merck

1 reference

https://pubmed.ncbi.nlm.nih.gov/26935578

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Accumulation of O6-methylguanine in human blood leukocyte DNA during exposure to procarbazine and its relationships with dose and repair.

1 reference

https://pubmed.ncbi.nlm.nih.gov/26935578

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The biology of integrins

1 reference

https://pubmed.ncbi.nlm.nih.gov/26935578

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S11060-016-2094-0

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39953290&oldid=2203278322"